D
Madrigal Pharmaceuticals, Inc.
MDGL
$309.94
-$0.58-0.19%
D
Sell
2/29/2024Upgraded
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D- from E+ on 2/29/2024 due to an increase in the solvency index, total return index and volatility index. The quick ratio increased from 2.33 to 5.35, and debt to equity declined from 5.18 to 0.29.
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D- from E+ on 2/29/2024 due to an increase in the solvency index, total return index and volatility index. The quick ratio increased from 2.33 to 5.35, and debt to equity declined from 5.18 to 0.29.
E
Sell
10/4/2023Downgrade
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to E+ from D- on 10/4/2023 due to a significant decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.56 to 0.96, and the quick ratio declined from 3.35 to 2.99.
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to E+ from D- on 10/4/2023 due to a significant decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.56 to 0.96, and the quick ratio declined from 3.35 to 2.99.
D
Sell
3/14/2023Downgrade
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the total return index.
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the total return index.
D
Sell
2/23/2023Upgraded
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index and volatility index.
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index and volatility index.
D
Sell
12/23/2022Upgraded
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D from E+ on 12/23/2022 due to a noticeable increase in the total return index and volatility index.
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D from E+ on 12/23/2022 due to a noticeable increase in the total return index and volatility index.
E
Sell
12/13/2022Downgrade
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to E+ from D- on 12/13/2022 due to a decline in the volatility index.
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to E+ from D- on 12/13/2022 due to a decline in the volatility index.
D
Sell
11/28/2022Upgraded
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D- from E+ on 11/28/2022 due to an increase in the volatility index.
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D- from E+ on 11/28/2022 due to an increase in the volatility index.
E
Sell
11/9/2022Downgrade
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to E+ from D- on 11/9/2022 due to a noticeable decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.59 to 4.66, the quick ratio declined from 2.52 to 1.55, and earnings per share declined from -$4.1354 to -$4.7474.
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to E+ from D- on 11/9/2022 due to a noticeable decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.59 to 4.66, the quick ratio declined from 2.52 to 1.55, and earnings per share declined from -$4.1354 to -$4.7474.
D
Sell
6/1/2022Downgrade
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to D- from D on 6/1/2022 due to a decline in the total return index and volatility index.
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to D- from D on 6/1/2022 due to a decline in the total return index and volatility index.
D
Sell
5/16/2022Upgraded
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to E+ from D on 05/13/2022.
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to E+ from D on 05/13/2022.
D
Sell
5/10/2022Upgraded
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D from D- on 5/10/2022 due to an increase in the growth index. Earnings per share increased from -$3.7804 to -$3.363, and EBIT increased 10.86% from -$64.6M to -$57.59M.
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D from D- on 5/10/2022 due to an increase in the growth index. Earnings per share increased from -$3.7804 to -$3.363, and EBIT increased 10.86% from -$64.6M to -$57.59M.
D
Sell
5/5/2022Upgraded
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to E+ from D- on 04/20/2022.
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to E+ from D- on 04/20/2022.
D
Sell
11/12/2021Upgraded
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D- from E+ on 11/12/2021 due to an increase in the growth index and solvency index. Operating cash flow increased 2.83% from -$46.88M to -$45.56M.
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D- from E+ on 11/12/2021 due to an increase in the growth index and solvency index. Operating cash flow increased 2.83% from -$46.88M to -$45.56M.
E
Sell
9/9/2021Downgrade
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to E+ from D- on 9/9/2021 due to a large decline in the total return index, volatility index and growth index. EBIT declined 16.54% from -$52.98M to -$61.74M, earnings per share declined from -$3.3172 to -$3.7203, and operating cash flow declined 7.95% from -$43.43M to -$46.88M.
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to E+ from D- on 9/9/2021 due to a large decline in the total return index, volatility index and growth index. EBIT declined 16.54% from -$52.98M to -$61.74M, earnings per share declined from -$3.3172 to -$3.7203, and operating cash flow declined 7.95% from -$43.43M to -$46.88M.
D
Sell
7/7/2021Downgrade
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to D- from D on 7/7/2021 due to a decline in the total return index.
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to D- from D on 7/7/2021 due to a decline in the total return index.
D
Sell
4/27/2021Upgraded
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D from D- on 4/27/2021 due to an increase in the total return index.
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D from D- on 4/27/2021 due to an increase in the total return index.
D
Sell
3/16/2021Downgrade
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to D- from D on 3/16/2021 due to a substantial decline in the growth index, volatility index and solvency index. Operating cash flow declined 14.83% from -$47.85M to -$54.95M, the quick ratio declined from 6.81 to 6.1, and earnings per share declined from -$3.752 to -$3.8205.
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to D- from D on 3/16/2021 due to a substantial decline in the growth index, volatility index and solvency index. Operating cash flow declined 14.83% from -$47.85M to -$54.95M, the quick ratio declined from 6.81 to 6.1, and earnings per share declined from -$3.752 to -$3.8205.
D
Sell
10/9/2018Downgrade
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to D from D+ on 10/9/2018 due to a significant decline in the total return index and volatility index.
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to D from D+ on 10/9/2018 due to a significant decline in the total return index and volatility index.
D
Sell
8/8/2018Upgraded
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D+ from D on 8/8/2018 due to a significant increase in the total return index, volatility index and efficiency index. Total capital increased 174.34% from $177.18M to $486.09M.
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D+ from D on 8/8/2018 due to a significant increase in the total return index, volatility index and efficiency index. Total capital increased 174.34% from $177.18M to $486.09M.
D
Sell
5/11/2018Upgraded
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D from D- on 5/11/2018 due to an increase in the growth index, efficiency index and solvency index. The quick ratio increased from 19.05 to 29.05, earnings per share increased from -$0.6704 to -$0.4505, and net income increased 24.64% from -$8.45M to -$6.36M.
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D from D- on 5/11/2018 due to an increase in the growth index, efficiency index and solvency index. The quick ratio increased from 19.05 to 29.05, earnings per share increased from -$0.6704 to -$0.4505, and net income increased 24.64% from -$8.45M to -$6.36M.
D
Sell
11/13/2017Downgrade
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to D- from D on 11/13/2017 due to a large decline in the volatility index, growth index and valuation index.
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to D- from D on 11/13/2017 due to a large decline in the volatility index, growth index and valuation index.
D
Sell
8/1/2017Upgraded
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D from D- on 8/1/2017 due to a major increase in the volatility index, growth index and total return index. Operating cash flow increased 28.58% from -$5.28M to -$3.77M, earnings per share increased from -$0.6484 to -$0.5018, and EBIT increased 2.89% from -$6.26M to -$6.08M.
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D from D- on 8/1/2017 due to a major increase in the volatility index, growth index and total return index. Operating cash flow increased 28.58% from -$5.28M to -$3.77M, earnings per share increased from -$0.6484 to -$0.5018, and EBIT increased 2.89% from -$6.26M to -$6.08M.
D
Sell
4/3/2017Upgraded
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D- from E on 4/3/2017 due to an increase in the valuation index.
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to D- from E on 4/3/2017 due to an increase in the valuation index.
E
Sell
1/3/2017Upgraded
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to E from E- on 1/3/2017 due to an increase in the total return index.
Madrigal Pharmaceuticals, Inc. (MDGL) was upgraded to E from E- on 1/3/2017 due to an increase in the total return index.
E
Sell
11/16/2016None
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to E- from U on 11/16/2016.
Madrigal Pharmaceuticals, Inc. (MDGL) was downgraded to E- from U on 11/16/2016.
NASDAQ
04/08/2025 1:41PM Eastern
Quotes delayed
